Form 4: Lucid Diagnostics CEO Aklog Lishan Reports Acquisition of 400,000 Shares of Restricted Stock

Lucid Diagnostics CEO Aklog Lishan reported the acquisition of 400,000 shares of restricted stock and provided an update on beneficial ownership.

Summary

• On May 7, 2024, Lucid Diagnostics CEO Aklog Lishan reported acquiring 400,000 shares of common stock.
• These shares were granted as restricted stock under the Issuer's 2018 Equity Plan and will vest on May 20, 2026, contingent upon continued service.
• The reporting person's total beneficial ownership of Lucid common stock following the transaction is 1,166,627 shares.
• This includes 142,227 shares distributed by PAVmed on February 15, 2024.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of restricted stock by the CEO is generally viewed as a positive sign, aligning his interests with the company's long-term performance. However, it's a routine filing and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of restricted stock by the CEO aligns his interests with the long-term success of the company.

Risks

• The restricted stock is subject to forfeiture if the service period is not completed, which could be a risk if the CEO were to leave the company before the vesting date.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The acquisition of restricted stock by the CEO could positively impact shareholder confidence.

Key Dates